Y-mAbs Therapeutics 2025 Q1 Earnings Solid Performance as Net Loss Narrows 21.6%

Y-mAbs Therapeutics (YMAB) reported its fiscal 2025 Q1 earnings on May 13th, 2025. The company demonstrated resilience in its first-quarter results with revenue growth of 4.9%, reaching $20.90 million compared to the previous year. Despite narrowing its net loss by 21.6%, Y-mAbs missed general expectations, maintaining guidance consistent with prior projections. The company remains committed to operational efficiency and innovation, with no adjustments to its full-year guidance.

Revenue
Y-mAbs Therapeutics reported a 4.9% increase in total revenue for the first quarter of 2025, reaching $20.90 million, compared to $19.93 million in the same period of 2024. The entirety of the revenue stemmed from net product sales, illustrating steady growth in this segment.

Earnings/Net Income
Y-mAbs Therapeutics improved its earnings performance by narrowing its losses to $0.12 per share in 2025 Q1 from a loss of $0.15 per share in 2024 Q1, marking a 20% improvement. The company reduced its net loss to $5.20 million, a 21.6% decrease from the previous year's $6.63 million net loss. The EPS improvement is positive, reflecting effective cost management and strategic initiatives.

Price Action
The stock price of Y-mAbs Therapeutics declined 7.14% during the latest trading day, increased 7.77% over the past week, and fell 4.37% month-to-date.

Post-Earnings Price Action Review
The investment strategy of acquiring Y-mAbs Therapeutics shares following a revenue decline on the financial report release date and holding for 30 days resulted in significant losses. Over the past five years, this strategy yielded a return of -90.74%, starkly underperforming against a benchmark return of 87.97% and an excess return of -178.71%. The strategy exhibited poor risk-adjusted returns, evidenced by a Sharpe ratio of -0.46, and a maximum drawdown of -95.22%, underscoring its high risk and substantial losses. Investors should exercise caution, given the strategy's historical performance and volatility.

CEO Commentary
Michael Rossi, President and Chief Executive Officer, expressed satisfaction with the first quarter of 2025, highlighting solid DANYELZA net product revenue and advancements in their SADA pretargeted radioimmunotherapy platform. He noted the successful dosing of the first patient in Trial 1201, emphasizing the potential of their innovative approach to enhance treatment outcomes for patients with relapsed/refractory non-Hodgkin Lymphoma. Rossi mentioned the operational restructuring into two business units, DANYELZA and Radiopharmaceuticals, which allows for clearer reporting of segment profits and resource investments aimed at bolstering their radioimmunotherapy initiatives.

Guidance
Management reiterates its full-year 2025 guidance, projecting total revenue between $17 million and $19 million for the second quarter of 2025. The company maintains its cash guidance, reporting cash and cash equivalents of $60.3 million as of March 31, 2025, reflecting a cash investment of $6.9 million in the first quarter, aligning with their full-year expectations.

Additional News
Y-mAbs Therapeutics recently announced that naxitamab-gqgk (DANYELZA®) has been recommended by the National Comprehensive Cancer Network® (NCCN) Clinical Practice Guidelines in Oncology as a Category 2A treatment option for high-risk neuroblastoma. Additionally, Y-mAbs dosed the first patient in its CD38-SADA Phase 1 clinical trial for relapsed/refractory non-Hodgkin Lymphoma. The company plans to host a virtual Radiopharmaceutical R&D update on May 28, 2025, discussing clinical data from its ongoing trials and announcing future radioimmunotherapy strategies. These developments highlight Y-mAbs' commitment to advancing its innovative cancer therapies and expanding its market presence.